Sudden Cardiac Death Clinical Trial
— TriQarrOfficial title:
Exploring Mechanisms and Morphology of QT Interval Prolongation - An Inheritable as Well as an Inducible Phenomenon
Verified date | February 2019 |
Source | Herlev and Gentofte Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The projects will try and optimise the risk stratification for patients with Long QT syndrome
by investigating how the exposure of physical and acoustic stress will affect the QT-dynamics
and if beta blockers protect against arrhythmias by suppressing this dynamic QT-prolongation.
Furthermore, the project will investigate the effects of Spironolactone on the QT-dynamics
tested by "Brisk Standing".
First, patients are tested with known arrhythmic triggers and they are then administered
thier normal dose of beta blockers. Hereafter, "Brisk Standing" test is performed and the
patients are on Spironolactone for seven days. After seven days treatment the "Brisk
Standing" is repeated.
Status | Completed |
Enrollment | 28 |
Est. completion date | January 1, 2019 |
Est. primary completion date | June 27, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Verified Long QT syndrome mutation, subtype 1 or 2. - over 18 years of age Exclusion Criteria: - Atrioventricular block, - Left bundle branch block, - Left ventricular hypertrophy, - Pace rhythm, - ST-deviations >1 mm), - Left ventricular ejection fraction <50 % and significant valvulopathy, - Unstable psychiatric disease - Unstable cardiovascular disease. |
Country | Name | City | State |
---|---|---|---|
Denmark | Herlev-Gentofte Hospital | Herlev | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Herlev and Gentofte Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | QTc | Corrected QT | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02923726 -
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
|
N/A | |
Recruiting |
NCT05175937 -
REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology
|
||
Completed |
NCT02026102 -
A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)
|
N/A | |
Completed |
NCT01262508 -
Development of Algorithms to Predict Hemodynamic Instability
|
N/A | |
Completed |
NCT00998218 -
Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction
|
Phase 3 | |
Completed |
NCT00845286 -
Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial
|
N/A | |
Active, not recruiting |
NCT00562757 -
Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias
|
N/A | |
Completed |
NCT00622453 -
Arrhythmias in Myotonic Muscular Dystrophy
|
N/A | |
Completed |
NCT03833843 -
Sudden Cardiac Death in Systemic Right Ventricle
|
||
Completed |
NCT04024865 -
Domperidone and Risk of Serious Cardiac Events in Postpartum Women
|
||
Recruiting |
NCT05799833 -
Low QRS Voltages in Young Healthy Individuals and Athletes
|
||
Recruiting |
NCT05694572 -
Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
|
||
Not yet recruiting |
NCT03622307 -
Subcutaneous ICD Therapy Combined With VT Ablation for the Secondary Prevention of Sudden Cardiac Death
|
N/A | |
Recruiting |
NCT02058771 -
Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
|
||
Recruiting |
NCT02056509 -
The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation.
|
N/A | |
Terminated |
NCT01948206 -
Study of Paced QRS Duration as a Marker of Sudden Cardiac Death
|
N/A | |
Completed |
NCT01227785 -
Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study
|
N/A | |
Terminated |
NCT00524862 -
Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death
|
N/A | |
Completed |
NCT00534300 -
Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker
|
Phase 1/Phase 2 | |
Recruiting |
NCT00181233 -
Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
|